JCA Pulse · The EU JCA trackerThe state of EU joint clinical assessment, today
PICO forecaster unlocked
Explore Pro
The register
Every technology, every status
Milestones
National status across Europe
Technologies with a public national record. Select a cell to open it.
A–Z index of technology pages
Technology index
Every technology in the EU JCA tracker
21 ongoing · 4 reports published · 4 discontinued
| Technology | Indication | Therapy area | Assessors | Open |
|---|---|---|---|---|
| Ongoing assessments 21 | ||||
| HighLife trans-septal mitral valve replacement systemHighLife SAS | Mitral regurgitation, unsuitable for surgery or TEER | Cardiovascular |  FR PL | |
| SAPIEN M3 transcatheter mitral valve replacement systemEdwards Lifesciences | Mitral regurgitation, unsuitable for surgery or TEER | Cardiovascular |  NL NO | |
| Autologous bioengineered skin substitute | Deep dermal and full-thickness burns | Dermatology & wounds | FR BE | |
| Lunsotogene parvecRegeneron | OTOF-related hearing loss | ENT & respiratory |  DENO | |
| Zopapogene imadenovecPrecigen | Recurrent respiratory papillomatosis | ENT & respiratory |  DK AT | |
| Mezigdomide | Relapsed/refractory multiple myeloma | Haematology | DEPL | |
| Pelabresib | Myelofibrosis | Haematology | NO EE | |
| SonrotoclaxBeOne Medicines | Relapsed/refractory mantle cell lymphoma | Haematology | BE SE | |
| Zamtocabtagene autoleucel | Large B-cell lymphoma, second line | Haematology | NL IE | |
| Rebisufligene etisparvovecUltragenyx | MPS IIIA (Sanfilippo A) | Metabolic & genetic | AT HU | |
| Bifikafusp alfa / onfekafusp alfa (Nidlegy)Philogen | Melanoma, neoadjuvant | Solid tumours | SEPL | |
| CamizestrantAstraZeneca | HR+/HER2− breast cancer, ESR1 switch | Solid tumours | ATBE | |
| CosibelimabCheckpoint Therapeutics | Cutaneous squamous cell carcinoma | Solid tumours | DEFR | |
| DaraxonrasibRevolution Medicines | Metastatic pancreatic cancer | Solid tumours | DEDK | |
| Ensartinib (Gevalka)SFL Pharmaceuticals / Betta | ALK-positive NSCLC | Solid tumours | AT ES | |
| FuzuloparibHengrui | mCRPC, first line | Solid tumours | DENL | |
| LirafugratinibElevar Therapeutics | FGFR2-altered cholangiocarcinoma | Solid tumours | SEAT | |
| Relacorilant (Lifyorli)Corcept Therapeutics | Platinum-resistant ovarian cancer | Solid tumours |  PTSE | |
| RezvilutamideHengrui | High-volume mHSPC | Solid tumours | NLIE | |
| Senaparib (Sepalna)SFL Pharmaceuticals | Ovarian cancer, first-line maintenance | Solid tumours | DE SI | |
| Taletrectinib | ROS1-positive NSCLC | Solid tumours | SEDE | |
| JCA reports published 4 | ||||
| Onasemnogene abeparvovec, intrathecal (Itvisma)Novartis | 5q spinal muscular atrophy, age 2+ | Neurology & neuromuscular | IEFR | |
| Lurbinectedin (Zepzelca)Pharma Mar | ES-SCLC, first-line maintenance | Solid tumours | DEPT | |
| Tarlatamab (Imdylltra)Amgen | ES-SCLC after first-line platinum | Solid tumours | DEHU | |
| Tovorafenib (Ojemda)Ipsen | Paediatric low-grade glioma | Solid tumours | IEDE | |
| Discontinued 4 | ||||
| Autologous TIL (Tacquell)Netherlands Cancer Institute | Melanoma | Solid tumours | FRPL | |
| CatequentinibAdvenchen Laboratories | Synovial sarcoma or leiomyosarcoma | Solid tumours | SENO | |
| SasanlimabPfizer | Bladder cancer | Solid tumours | NLDK | |
| SintilimabInnovent / Eli Lilly | Non-squamous NSCLC | Solid tumours | DE SK | |
JCA Pulse Pro · Founding access now open
See your JCA coming, and plan every market around it
The free tracker tells you what is happening. Pro tells you what it means for your product: how well the evidence fits each likely PICO, which comparisons the dossier will need, and what the outcome could mean for price and access across 31 markets.
- 01Go into scoping preparedEvidence-fit scores for every likely PICO, with the evidence gaps to close while there is still time to close them.
- 02Build the right comparisons earlyEvery relevant trial, the evidence network and the indirect comparison each comparator is likely to need.
- 03Sequence your launches with confidenceThe national translator: what the JCA means for the route, timing and price in each of 31 European markets.
- 04Stay ahead of every milestoneAlerts and watchlists for your portfolio and competitors, with CSV export and analyst briefings on team plans.
Built forMarket access and HEOR teams · Launch and portfolio leads · Agencies and consultancies · Academics and students, at a reduced rate
Pro Individual from €79 a month
Monthly or yearly · cancel monthly plans any time · founding rates for early subscribers
Not ready yet? and see the quality of the analysis first.
Need the full country view for your product? Book a free 30-minute call.
info@evidaxia.comHow to cite this page
Cite the page you are viewing. The citation updates as you move between pages.